Bilateral implantation of +3.0 D multifocal toric intraocular lenses: results of a US Food and Drug Administration clinical trial

Abstract This spotlight review focuses on the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food and Drug Administration. This drug was approved for patients with multiple myeloma who have received at least 2 prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. This review focuses on the clinical trial data that led to approval and provides advice for treating physicians who are now prescribing this drug for patients.

Download Full-text

One-year evaluation of myopic laser photoastigmatic refractive keratectomy using the Summit Apex Plus Phase III of a Food and Drug Administration clinical trial

Ophthalmology ◽

10.1016/s0161-6420(00)00193-7 ◽

2000 ◽

Vol 107 (8) ◽

pp. 1572-1577 ◽

Cited By ~ 4

Author(s):

W Haw

Keyword(s):

Clinical Trial ◽

Drug Administration ◽

Food And Drug Administration ◽

Phase Iii ◽

One Year

Download Full-text

Intramuscular neuromuscular electric stimulation for poststroke shoulder pain: A multicenter randomized clinical trial 11A commercial party with a direct financial interests in the results of the research supporting this article has or will confer a benefit on the author or 1 or more of the authors. NeuroControl Corp, Valley View, OH, intends to commercialize the device evaluated in this article and has submitted a premarket 510(K)application, which is currently pending US Food and Drug Administration review. Chae and Feldstein are consultants to NeuroControl. Walker was an employee of NeuroControl, and is now a consultant to NeuroControl. Fang is an employee of NeuroControl. During this study, Yu served as a consultant to NeuroControl and Grill was an employee of NeuroControl, but neither now has an affiliation with NeuroControl.

Archives of Physical Medicine and Rehabilitation ◽

10.1016/j.apmr.2003.07.015 ◽

2004 ◽

Vol 85 (5) ◽

pp. 695-704 ◽

Cited By ~ 61

Author(s):

David T Yu ◽

John Chae ◽

Maria E Walker ◽

Andrew Kirsteins ◽

Elie P Elovic ◽

...

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Shoulder Pain ◽

Drug Administration ◽

Electric Stimulation ◽

Food And Drug Administration ◽

Financial Interests

Download Full-text

Non-US Clinical Trial Data and the Food and Drug Administration

Clinical Research Practices and Drug Regulatory Affairs ◽

10.3109/10601338709032968 ◽

1987 ◽

Vol 5 (5-6) ◽

pp. 381-409

Author(s):

Michael Weintraub

Keyword(s):

Clinical Trial ◽

Drug Administration ◽

Food And Drug Administration ◽

Clinical Trial Data ◽

Trial Data

Download Full-text

Evaluation of the small-aperture intracorneal inlay: Three-year results from the cohort of the U.S. Food and Drug Administration clinical trial

Journal of Cataract & Refractive Surgery ◽

10.1016/j.jcrs.2018.02.023 ◽

2018 ◽

Vol 44 (5) ◽

pp. 541-556 ◽

Cited By ~ 13

Author(s):

John A. Vukich ◽

Daniel S. Durrie ◽

Jay S. Pepose ◽

Vance Thompson ◽

Corina van de Pol ◽

...

Keyword(s):

Clinical Trial ◽

Drug Administration ◽

Food And Drug Administration ◽

Small Aperture ◽

The U.S

Download Full-text

Results of the U.S. Food and Drug Administration Continued Access Clinical Trial of the GORE HELEX Septal Occluder for Secundum Atrial Septal Defect

JACC Cardiovascular Interventions ◽

10.1016/j.jcin.2014.01.169 ◽

2014 ◽

Vol 7 (8) ◽

pp. 905-912 ◽

Cited By ~ 15

Author(s):

Alexander J. Javois ◽

Jonathan J. Rome ◽

Thomas K. Jones ◽

Evan M. Zahn ◽

Craig E. Fleishman ◽

...

Keyword(s):

Clinical Trial ◽

Atrial Septal Defect ◽

Drug Administration ◽

Septal Defect ◽

Food And Drug Administration ◽

Secundum Atrial Septal Defect ◽

Helex Septal Occluder ◽

The U.S

Download Full-text